[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"magnesium\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:magnesium":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,71,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100641205","phase-2-oral-versus-intravenous-magnesium-on-emergence-delirium-100641205",false,"NCT07655817","Oral Versus Intravenous Magnesium on Emergence Delirium","Effect of Oral Versus Intravenous Magnesium on Emergence Delirium in Children Undergoing Adenotonsillectomy: A Two-Center, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* Children aged 4 to 7 years\n* American Society of Anesthesiologist (ASA) Status I or II\n* Planned for an adenotonsillectomy procedure under sevoflurane general anesthesia.\n\nExclusion Criteria:\n\n* Parents declined to participate in the trial\n* Behavioral changes, neurological or psychiatric problems\n* Anticonvulsant or sedative drugs\n* Physical or developmental abnormalities\n* Allergies to magnesium\n* cardiovascular, renal, bone, or gastrointestinal diseases.","ALL","4 Years","7 Years",{"count":20,"type":21},360,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","This prospective randomized controlled study will be conducted to compare the effects of preoperative oral magnesium and intraoperative IV magnesium on the incidence and severity of emergence delirium in children undergoing adenotonsillectomy using sevoflurane anesthesia.",[28,29,30,31],"Magnesium","Emergence Delirium","Children","Adenotonsillectomy","NOT_YET_RECRUITING","2026-06-13",{"date":35,"type":36},"2026-06-18","ACTUAL",{"date":38,"type":21},"2026-06-24",{"date":40,"type":21},"2026-12-25",{"name":42,"class":43},"Tanta University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100449441","magnesium-and-cognition-after-stroke-100449441","NCT05132517","Magnesium and Cognition After Stroke","Relationship Between Magnesium Concentration in Blood and Kognitive Functions After Stroke","Inclusion Criteria:\n\n* ischemic\u002Fhemmorhagic stroke\n* written consent form\n\nExclusion Criteria:\n\n* pre-existing dementia or cognitive impairment before stroke onset\n* pre-existing mental disorder (depression) or present\u002Fprior long-term treatment (\\> 6 months) with psychotropic drugs\n* pre-existing malign tumor disease\n* participation in another clinical trial within the past 30 days\n* pregnancy or breastfeeding","18 Years",{"count":54,"type":21},80,"OBSERVATIONAL","Cognitive impairments such as memory impairments, word-finding difficulties, compromised orientation and perception are often observed in stroke patients.\n\nLow serum-mg-concentrations are associated with cognitive impairments in ischemic stroke patients one month after stroke onset. It is not clear, if cognitive impairments after stroke is caused by the mg-deficiency or by the stroke itself. Until now, no studies investigating the relationship between mg-concentration, stroke severity and cognition during treatment course are available. Thus, this study aimed to investigate the relationship between mg-concentration and cognition of stroke patients.",[58,59,28,60],"Stroke","Cognition","Neurologic Disorder","RECRUITING","2026-04-16",{"date":64,"type":36},"2026-04-20",{"date":66,"type":36},"2022-10-26",{"date":68,"type":21},"2027-09-30",{"name":70,"class":43},"BDH-Klinik Hessisch Oldendorf",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":44},"100618972","magnesium-in-gastrointestinal-disease-100618972","NCT07338565","Magnesium in Gastrointestinal Disease","Magnesium Status in Patients With Gastrointestinal Disease","MAGIC","Inclusion Criteria:\n\n\\- Age 18 or older, mentally competent, and able to understand Danish.\n\nGroup 1:\n\n\\- Diagnosed with IBD (DK50X, Crohn's disease, or DK51X, ulcerative colitis), ileostomy (DZ932) or bile acid diarrhoea (DSK908B) (Se-HCAT scintigraphy showing residual activity \\\u003C10%).\n\nGroup 2:\n\n\\- Healthy individuals.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Use of oral magnesium supplements for more than 2 weeks before inclusion.",true,{"count":81,"type":21},120,"Individuals with gastrointestinal diseases - such as Crohn's disease, ulcerative colitis, ileostomy, or bile acid diarrhoea - are at increased risk of magnesium deficiency. Magnesium is a vital mineral that supports many essential functions in the body, including muscle contraction, nerve signalling, heart rhythm, and bone health. Deficiency may contribute to fatigue, muscle cramps, abnormal heart rhythms, and reduce the quality of life.\n\nThe purpose of this study is to investigate the prevalence of magnesium deficiency in individuals with these conditions and to identify the most accurate and practical methods for assessing magnesium status in clinical care.\n\nAlthough plasma magnesium is commonly used in routine blood tests, it represents only about 1% of the body's total magnesium and may not reflect true magnesium levels within cells or tissues. Hence, this study compares several different ways of measuring magnesium, including:\n\n* Plasma magnesium\n* Magnesium levels in red and white blood cells (PBMC, RBC, and buffy coat)\n* Magnesium levels in muscle tissue (via biopsy)\n* A magnesium retention test, based on how much magnesium is excreted after an infusion\n\nThe study includes four groups:\n\n1. Patients with inflammatory bowel disease.\n2. Patients with an ileostomy.\n3. Patients with bile acid diarrhoea.\n4. Healthy individuals (control group).\n\nAll participants will provide blood and urine samples, and some may undergo optional biopsies of muscle or intestinal tissue. Participants will also complete questionnaires and undergo tests of muscle strength and body composition.\n\nThe findings are expected to enhance the understanding and detection of magnesium deficiency in patients with gastrointestinal diseases and to aid in the development of more effective tools for identifying and treating this common yet often overlooked condition.",[84,85,86,87,88,89,90,91,92,93,94,28],"Colitis Ulcerosa","Colitis Ulcerative","Crohns Disease","Morbus Crohn","Ileostomy - Stoma","Ileostoma","Ileostomies","Bile Acid Diarrhea","Bile Acid Malabsorption","Magnesium Deficiency","Magnesium Level","2026-01-05",{"date":97,"type":36},"2026-01-14",{"date":99,"type":36},"2025-11-03",{"date":101,"type":21},"2027-12-01",{"name":103,"class":43},"University of Aarhus",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":79,"sex":111,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":44},"100589848","magnesium-l-threonate-improves-menopausal-symptoms-100589848","NCT06959745","Magnesium-L-Threonate Improves Menopausal Symptoms","Magnesium-L-Threonate Improves Menopausal Symptoms: A Single-center, Single-blind, Randomized, Placebo-Controlled Pilot Study","Inclusion Criteria:\n\n1. Women aged 40-60 years;\n2. Postmenopausal status or in the late menopausal transition stage. 3. Postmenopausal status is defined as: natural menopause with no menstruation in the past 12 months. The late menopausal transition stage will be defined as: amenorrhea for at least 60 days within the past 12 months;\n\n4\\. MRS score ≥15 points based on symptoms in the past 1 month; 5. Willing to complete the required follow-up visits during the trial period. 6. Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. History of bilateral oophorectomy or hysterectomy;\n2. Current or past use of magnesium L-threonate preparations or similar nutrient formulations within the last 3 months;\n3. Definite history of gastrointestinal diseases that may affect the absorption of the investigational drug;\n4. Definite history of liver diseases that may affect the metabolism of the investigational drug;\n5. Definite history of kidney diseases that may affect the excretion of the investigational drug, with serum creatinine levels \\> 2 mg\u002FdL (88.4 μmol\u002FL);\n6. Current or recent use of hormone replacement therapy: vaginal or transdermal estrogen within the past 4 weeks; oral estrogen or progesterone within the past 8 weeks; intrauterine progesterone therapy within the past 8 weeks; progesterone implants or estrogen injection therapy within the past 3 months; estrogen pellet therapy or progesterone injection therapy within the past 6 months; or intention to use these medications during the intervention period;\n7. Current or past use of medications such as clonidine, methyldopa, gabapentin, pregabalin, and selective serotonin or norepinephrine reuptake inhibitors (SSRIs\u002FSNRIs) within the past 1 month, or intention to use these medications during the intervention period;\n8. Current or past use of phosphodiesterase inhibitor medications within the past 1 month, or intention to use these medications during the intervention period;\n9. Autoimmune diseases requiring medication, current or past treatment with glucocorticoids, antirheumatic drugs, or biologics within the past 6 months, or intention to use these medications during the intervention period;\n10. Depression or anxiety requiring medication, current or past use of antidepressants within the past 3 months, or intention to use these medications or treatments during the intervention period;\n11. Current or past use of hypnotic medications such as diazepam or triazolam within the past 2 weeks, or intention to use these medications during the intervention period;\n12. Osteoarthritis, osteoporosis, or other musculoskeletal diseases requiring medication;\n13. Known allergy to magnesium L-threonate;\n14. History of malignancy, or life expectancy less than 1 year;\n15. Major surgery within the past 6 months, or intention to undergo surgery during the intervention period, including but not limited to cardiac surgery or joint replacement;\n16. Currently pregnant, having given birth within the past 3 months, planning pregnancy during the study period, or unwilling to use conventional barrier contraception or abstain from sexual activity to prevent pregnancy if not fully menopausal;\n17. Currently breastfeeding, having breastfed within the past 3 months, or planning to breastfeed during the study period;\n18. Unable or unwilling to provide informed consent, complete questionnaires, or attend study visits;\n19. Participation in other interventional studies;\n20. Other conditions judged by the investigator as unsuitable for trial participation. These conditions may make potential participants highly unlikely to adhere to the study protocol, including plans to relocate, substance abuse, severe psychiatric issues, or severe dementia.","FEMALE","40 Years","60 Years",{"count":115,"type":21},50,[117],"NA","This trial has a randomized, single-blind, single-center, parallel-controlled design, with participant screening and trial implementation conducted at Guangdong Provincial People's Hospital. The study evaluate the efficacy of oral magnesium L-threonate supplementation on improving menopausal symptoms and quality of life among peri\u002Fpost-menopausal women.\n\nThis trial aims to explore whether oral magnesium L-threonate supplementation could alleviate menopausal syndromes.\n\nParticipants will randomly assigned to conduct oral magnesium L-threonate supplementation or placebo for 8 weeks. Face-to-face and internet follow up will be conducted once per 2 weeks.",[120,28],"Menopause Syndrome",[122],"menopause syndrome","2025-05-04",{"date":125,"type":36},"2025-05-07",{"date":127,"type":21},"2025-05-15",{"date":129,"type":21},"2025-12-30",{"name":131,"class":43},"Guangdong Provincial People's Hospital"]